{"id":"NCT01766401","sponsor":"Forest Laboratories","briefTitle":"Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-31","primaryCompletion":"2014-01-29","completion":"2014-01-29","firstPosted":"2013-01-11","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":["Dose-matched placebo tablets, oral administration, once per day"]},{"type":"DRUG","name":"Vilazadone","otherNames":["Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vilazadone","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).","primaryOutcome":{"measure":"Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":14.9,"sd":7.37},{"arm":"Vilazadone","deltaMin":13.5,"sd":7.41}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0438"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["27486544","26291335"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":198},"commonTop":["Diarrhoea","Nausea","Headache","Dizziness","Dry mouth"]}}